Ivosidenib

In this video, Afsaneh Barzi, MD, PhD, discusses the results of the CheckMate 8HW study.

In this video, Rachna T. Shroff, MD, MS, discusses data from the CIRCULATE and COBRA studies, which evaluated the role of circulating tumor DNA in guiding treatment decisions for patients with colon cancer.

In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

The FDA approved ivosidenib for treatment of certain adults with relapsed or refractory myelodysplastic syndromes.

The FDA announced several regulatory actions the past few weeks.

Healio spoke with David Andrew Sallman, MD, about treatments in the pipeline and ongoing research in myelodysplastic syndrome.

This year’s ASCO Annual Meeting included essential research updates across the field.

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemia and more.

CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.